BioTech Medics, Inc. Upgraded on OTC Markets
Published: Apr 30, 2012
DALLAS, TX--(Marketwire - April 30, 2012) -
BioTech is preparing a major products branding campaign for the balance of 2012. BioTech is a 14-year-old company that has completed major R&D over its health products that are alternatives for the 21st century. The company marketing initiative will emphasize its superior brands.
During the past year BioTech has been searching companies to enter in a $5 million cross-marketing advertising campaign of one or more of BioTech's proprietary products. The company anticipates entering into an agreement by the third quarter.
BioTech sells SHBAN™ Alcohol Free Persistent Antiseptic. SHBAN is a unique product superior to most antiseptics because it is longer lasting, is gentle on the skin and is non-flammable. In addition, SHBAN can also be used on minor cuts, wounds and scraps. One major advantage of SHBAN is that it can be used in the nose where germs and viruses are inhaled. The World Health Organization (WHO) has recommended antiseptics with "persistent antimicrobial activity." SHBAN is protected with four US Patents. www.shban.com
Additionally, BioTech owns and sells BioBody Balance™ Products. BioBody has been a successful brand with over $5 million in prior sales through multi-level marketing, Internet and retail. Recently, BioTech announced the reformation of BioBody Balance into a new Energy Spray. The BioBody Energy Spray does not contain caffeine, but rather uses a vitamin B-Complex with 10 other proprietary supplemental dietary ingredients that give a person's body a natural energy lift while also stabilizing the user's metabolism without harmful stimulants. BioBody is used sublingually for maximum absorption into the blood stream. BioBody is currently available via the Internet at www.biobodybalance.com.
BioTech also operates BioTech Laser Pain Centers via affiliation agreements with 5 centers in 4 states. The laser centers use high powered deep penetrating FDA cleared lasers to treat over 90 types of muscle, nerve, bone or arthritic pain.
Statements in this release may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements may involve risks, estimates and uncertainties subject to third party acts or failure to act and market conditions.